Obatoclax for Systemic Mastocytosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
LeukemiaSystemic Mastocytosis
Interventions
DRUG

Obatoclax Mesylate

30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gemin X

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00918931 - Obatoclax for Systemic Mastocytosis | Biotech Hunter | Biotech Hunter